| 000 | 01681 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518090425.0 | ||
| 264 | 0 | _c20200422 | |
| 008 | 202004s 0 0 eng d | ||
| 022 | _a1873-135X | ||
| 024 | 7 |
_a10.1016/j.mrfmmm.2020.111690 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aIida, M | |
| 245 | 0 | 0 |
_aTargeting AKT/PKB to improve treatment outcomes for solid tumors. _h[electronic resource] |
| 260 |
_bMutation research _c |
||
| 300 |
_a111690 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_a3-Phosphoinositide-Dependent Protein Kinases _xgenetics |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDNA Damage |
| 650 | 0 | 4 |
_aDNA Repair _xdrug effects |
| 650 | 0 | 4 |
_aDNA, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aGamma Rays _xtherapeutic use |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoenzymes _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 |
_aNeoplasms _xenzymology |
| 650 | 0 | 4 |
_aPhosphatidylinositol 3-Kinases _xgenetics |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-akt _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSignal Transduction |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aras Proteins _xgenetics |
| 700 | 1 | _aHarari, P M | |
| 700 | 1 | _aWheeler, D L | |
| 700 | 1 | _aToulany, M | |
| 773 | 0 |
_tMutation research _gvol. 819-820 _gp. 111690 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.mrfmmm.2020.111690 _zAvailable from publisher's website |
| 999 |
_c30694166 _d30694166 |
||